Suppr超能文献

比较桂利嗪和茶苯海明固定低剂量联合与倍他司汀治疗前庭神经炎的疗效:一项随机、双盲、非劣效性研究。

Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.

机构信息

Department of Otorhinolaryngology, University of Innsbruck, Innsbruck, Austria.

出版信息

Clin Drug Investig. 2012 Jun 1;32(6):387-99. doi: 10.2165/11632410-000000000-00000.

Abstract

BACKGROUND

Vestibular neuritis (VN) is a strongly disabling disease of the peripheral vestibular system. Rapid and effective relief of symptoms is important to allow patients to promptly return to normal physical activity.

OBJECTIVE

The aim of this prospective, randomized, double-blind study was to evaluate the efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate in unilateral VN in comparison with betahistine in terms of improvement of vertigo and concomitant symptoms, and performance in neurotological testing.

METHODS

Sixty-two patients were randomized to receive either cinnarizine 20 mg/dimenhydrinate 40 mg as a fixed combination or betahistine 12 mg, each three times daily for 4 weeks. Vertigo and concomitant symptoms, activities of daily living (ADL), posturography and a battery of vestibulo-ocular tests, registered by electronystagmography including spontaneous nystagmus, bithermal caloric and rotatory test, among others, were assessed at baseline (t(0)), after 1 week (t(1w)) and after 4 weeks (t(4w)). The primary endpoint was the Mean Vertigo Score (MVS) at t(1w), a composite of 12 individual scores for unprovoked and provoked vertigo, each assessed using a 10 cm visual analogue scale (VAS). Non-inferiority of the fixed combination versus betahistine would be assumed if the two-sided 95% confidence intervals (CIs) for between-group differences in MVS lay entirely below the non-inferiority margin of 1.25 (12.5% of VAS range).

RESULTS

The fixed combination led to significantly greater improvements in MVS than betahistine both at t(1w) (primary endpoint) and at t(4w) (95% CI for the difference in baseline-adjusted means -0.95, -0.64 at t(1w), -0.77, -0.44 at t(4w); p < 0.001). Vegetative symptoms and ADL also improved significantly more under the fixed combination than under betahistine at t(1w) (p < 0.001, each parameter) and t(4w) (p < 0.001 and p < 0.01, respectively), both showing a nearly complete remission at t(4w). In the two groups, pathological posturography and electronystagmography parameters normalized during the 4-week treatment. The fixed combination group showed an earlier recovery of spontaneous nystagmus than the betahistine group (t(1w), p < 0.001) and slightly higher improvements in asymmetry of rotation-induced nystagmus at t(1w) and t(4w) (p = 0.041, each time point). No significant differences were found between the treatments in abatement of spontaneous nystagmus at t(4w) and decrease of caloric lateralization or improvement of equilibrium (sensory organization test [SOT], conditions 5/6) at t(1w) and t(4w). No patient reported any adverse event.

CONCLUSION

The results showed that the fixed low-dose combination of cinnarizine and dimenhydrinate is an effective and well tolerated option for symptomatic treatment in unilateral VN. The fixed combination led to significant improvements in vertigo and ADL within the first week, and to a nearly complete recovery after 4 weeks. Neurotological testing revealed no signs of a possible detrimental influence of the 4-week treatment with the fixed combination compared with betahistine in terms of recovery of caloric responsiveness and abatement of rotation-induced nystagmus.

摘要

背景

前庭神经炎(VN)是一种强烈致残的外周前庭系统疾病。快速有效地缓解症状对于患者尽快恢复正常的身体活动非常重要。

目的

本前瞻性、随机、双盲研究旨在评估与倍他司汀相比,固定低剂量桂利嗪和茶苯海明联合治疗单侧 VN 在改善眩晕和伴随症状方面的疗效,以及在神经耳科学测试中的表现。

方法

62 名患者随机分为接受桂利嗪 20mg/茶苯海明 40mg 固定联合治疗或倍他司汀 12mg,每日三次,持续 4 周。在基线(t(0))、第 1 周(t(1w))和第 4 周(t(4w))评估眩晕和伴随症状、日常生活活动(ADL)、姿势描记术和一系列前庭眼动测试,包括自发性眼震、双温测和旋转试验等,通过眼震电图记录。主要终点是 t(1w)时的平均眩晕评分(MVS),这是未经激发和激发性眩晕的 12 个个体评分的组合,每个评分均使用 10cm 视觉模拟量表(VAS)评估。如果双侧 95%置信区间(CI)落在 1.25(VAS 范围的 12.5%)以下,则假设固定联合与倍他司汀之间的组间差异的非劣效性。

结果

与倍他司汀相比,固定联合在 t(1w)(主要终点)和 t(4w)(基线调整均值的差异的 95%CI-0.95,-0.64 在 t(1w),-0.77,-0.44 在 t(4w);p<0.001)时均能显著改善 MVS。与倍他司汀相比,固定联合在 t(1w)(p<0.001,每个参数)和 t(4w)(p<0.001 和 p<0.01,分别)时也能显著改善植物性症状和 ADL,两组在 t(4w)时均显示出几乎完全缓解。在两组中,病理性姿势描记术和眼震电图参数在 4 周治疗期间正常化。与倍他司汀组相比,固定联合组的自发性眼震恢复更快(t(1w),p<0.001),并且在 t(1w)和 t(4w)时旋转诱发眼震的不对称性改善稍高(p=0.041,每次)。在 t(4w)时自发眼震的减轻和热量侧化的减少或平衡(感觉组织测试[SOT],条件 5/6)的改善方面,治疗之间未发现显著差异在 t(1w)和 t(4w)时。没有患者报告任何不良反应。

结论

结果表明,桂利嗪和茶苯海明的固定低剂量联合是单侧 VN 症状治疗的有效且耐受良好的选择。固定联合在第一周内显著改善了眩晕和 ADL,在四周后几乎完全恢复。神经耳科学测试显示,与倍他司汀相比,在恢复热量反应性和减轻旋转诱发眼震方面,四周的固定联合治疗没有迹象表明可能对治疗产生不利影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验